Recent Price Movement and Market Context
On 9 December 2025, Lincoln Pharmaceuticals recorded its lowest price in the past year at Rs.470.15. This level represents a notable drop from its 52-week high of Rs.975, indicating a decline of over 50% within the last twelve months. The stock has underperformed its sector peers, falling by 1.15% on the day and underperforming the Pharmaceuticals & Biotechnology sector by 1.11%.
Over the last four trading sessions, Lincoln Pharmaceuticals has delivered a cumulative return of -5.8%, reflecting a consistent downward trajectory. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish trend.
In contrast, the broader market index, Sensex, has shown relative resilience. Despite opening 359.82 points lower, Sensex closed down by 340.58 points at 84,402.29, a decline of 0.82%. The index remains within 2.08% of its 52-week high of 86,159.02 and is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a generally bullish market environment.
Rising fast and still accelerating! This Small Cap from FMCG sector is riding pure momentum right now. Jump in before the rally reaches its peak!
- - Accelerating price action
- - Pure momentum play
- - Pre-peak entry opportunity
Financial Performance and Growth Trends
Lincoln Pharmaceuticals has exhibited subdued growth over the medium term. Net sales have shown an annual growth rate of 9.21% over the past five years, while operating profit has grown at a rate of 5.37% during the same period. These figures suggest modest expansion relative to industry benchmarks.
Recent quarterly results indicate a contraction in profitability. The Profit After Tax (PAT) for the quarter stood at Rs.19.98 crores, reflecting a decline of 24.1% compared to the previous corresponding period. Similarly, Profit Before Tax excluding other income (PBT less OI) was Rs.21.58 crores, down by 12.98%. The Return on Capital Employed (ROCE) for the half year is reported at 15.46%, marking the lowest level in recent assessments.
Over the past year, the company’s profits have fallen by 17.2%, aligning with the downward trend in its share price. The stock’s one-year return of -50.47% contrasts sharply with the Sensex’s positive return of 3.55% over the same period, highlighting the stock’s relative underperformance.
Despite the company’s size, domestic mutual funds hold no stake in Lincoln Pharmaceuticals. Given their capacity for detailed research, this absence may reflect a cautious stance towards the company’s current valuation or business outlook.
Valuation and Balance Sheet Considerations
Lincoln Pharmaceuticals maintains a low average debt-to-equity ratio of zero, indicating a debt-free capital structure. This conservative financial position reduces leverage risk and may provide flexibility in capital allocation.
The company’s Return on Equity (ROE) stands at 11.2%, which, combined with a Price to Book Value ratio of 1.4, suggests an attractive valuation relative to its peers. The stock is trading at a fair value when compared to historical averages within the Pharmaceuticals & Biotechnology sector.
However, the stock’s performance over the last three years and recent months has been below the BSE500 benchmark, reflecting challenges in sustaining growth momentum.
Considering Lincoln Pharmaceuticals ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Sector and Market Dynamics
The Pharmaceuticals & Biotechnology sector has experienced mixed performance in recent months, with some stocks showing resilience while others face headwinds. Lincoln Pharmaceuticals’ recent price action contrasts with the broader market’s relative stability, as indicated by the Sensex’s proximity to its 52-week high and its position above key moving averages.
The stock’s current trading below all major moving averages signals a cautious market sentiment towards the company. This technical positioning may reflect concerns about the company’s recent financial results and growth prospects within a competitive industry landscape.
While the company’s valuation metrics suggest a reasonable price relative to book value and return on equity, the sustained decline in share price and profitability metrics highlight ongoing challenges in maintaining investor confidence.
Summary of Key Metrics
To summarise, Lincoln Pharmaceuticals’ stock has reached Rs.470.15, its lowest level in the past year, after a series of declines over four consecutive trading days. The stock’s one-year return of -50.47% contrasts with the Sensex’s positive 3.55% return, underscoring its relative underperformance. Profitability indicators such as PAT and PBT less other income have shown declines in recent quarters, while growth rates for net sales and operating profit remain modest.
The company’s balance sheet remains conservative with no debt, and valuation metrics such as ROE and Price to Book Value indicate a fair market price relative to peers. However, the absence of domestic mutual fund holdings and the stock’s position below all major moving averages reflect a cautious market stance.
Overall, Lincoln Pharmaceuticals’ recent price movement to a 52-week low highlights the challenges faced by the company amid a mixed sector environment and broader market fluctuations.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
